The accelerating need for pharmacovigilance

Journal of the Royal College of Physicians of London

Volumn 34, Issue 1, 2000, Pages 48-51

  Edwards, I Ralph ^a  

^a UPPSALA MONITORING CENTRE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG; SILDENAFIL;

DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG MARKETING; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HUMAN; IMPOTENCE; REVIEW;

DATABASES, FACTUAL; DRUG INDUSTRY; HUMANS; PATIENT SELECTION; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 0033998575     PISSN: 00358819     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (5)

1. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998;338: 1397-404.
2. Rendell MS, Rajfer J, Wicker PA, Smith MD. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomised controlled trial. Sildenafil Diabetes Study Group. JAMA 1999;281: 465-6.
3. Bortolotti A, Parazzini F, Colli E, Landoni M. The epidemiology of erectile dysfunction and its risk factors. Int J Androl 1997;20: 323-34.
4. Shah PK, Schwartz I, Saldana MJ, Villaran C, et al. Sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998;339:699-702.
5. Viagra effective treatment for diabetes-related impotence (1999) Doctor's Guide (0300h, 3 Mar 99) http://www.pslgroup.com